insights_auto
Why is AXGN up 2,61%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
50,02 $
arrow_upward
+2,61%(+1,27) 1D
50,00 $
arrow_downward
-0,04% (-0,020)todayPre-market
Closed: 6 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
48,55 $
High
50,29 $
Low
48,14 $
Mkt. cap
2,99 մլրդ
Avg. vol.
1,81 մլն
Volume
0,00
52-wk high
52,91 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 մլն
No. of employees
622
Open
48,55 $
High
50,29 $
Low
48,14 $
Mkt. cap
2,99 մլրդ
Avg. vol.
1,81 մլն
Volume
0,00
52-wk high
52,91 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 մլն
No. of employees
622
News stories
From web sources and news partners
Stocktwits
·
16 րոպե առաջ
Fox Just Added $100M+ Households To Its Streaming Ambitions: What’s Happening With Roku, InMed And Axalta?
Benzinga
·
30 րոպե առաջ
History Suggests Last Week's Selloff Was a Buying Opportunity - State Street SPDR S&P 500 ETF Trust (ARCA
WTNH.com
·
2 ժամ առաջ
Asian markets bounce back after a recovery for AI stocks on Wall Street
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Ֆլորիդա, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websiteaxogeninc.com